Navigation Links
Catalyst Pharmaceutical Partners, Inc. Announces Top-Line Results,of Its Bioequivalence Study of CPP-109 (Vigabatrin), the Company's,Investigational Drug to Treat Cocaine and Methamphetamine Addiction

atening condition for which there is no effective treatment and which demonstrates the potential to address unmet medical needs. For more information about the Company, go to www.catalystpharma.com.

This press release contains forward-looking statements. Forward-looking statements involve known and unknown risks and uncertainties which may cause the Company's actual results in future periods to differ materially from forecasted results. A number of factors, including that the final results of our bioequivalence study will be consistent with the top-line results received to date and those described in the Annual Report on Form 10-K that the Company has filed with the U.S. Securities and Exchange Commission ("SEC") reporting its financial position and results of operations as of and for the year ended December 31, 2006, could adversely affect the Company's ability to obtain these results. Copies of the Company's filings with the SEC are available from the SEC or may be obtained upon request from the Company. The Company does not undertake any obligation to update the information contained herein, which speaks only as of this date.

CONTACT: Patrick J. McEnany, Chief Executive Officer, +1-305-529-2522,, or Jack Weinstein, Chief Financial Officer,+1-201-934-4201, , both of CatalystPharmaceutical Partners; media, Tina Posterli, Rx Communications Group,+1-917-322-2565, pmcenany@catalystpharma.com jweinstein@catalystpharma.com tposterli@rxir.com

Web site: http://www.catalystpharma.com//

Ticker Symbol: (NASDAQ-NMS:CPRX)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All ri
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Materia Licenses Metathesis Catalyst Platform to Eisai
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
6. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
7. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
8. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
Post Your Comments:
(Date:10/22/2014)... WESTMINSTER, Colo. , Oct. 22, 2014   ... class of infusion systems designed to maximize targeted delivery ... is pleased to announce that oncologist John R. ... Norris Comprehensive Cancer Center, and surgical oncologist Steven ... Center have joined the Company,s Scientific Advisory Board (SAB).  ...
(Date:10/22/2014)... , Oct. 22, 2014 Sanomedics International ... 2014 report by Global Research & Data Services, demand ... year from 2014 through 2018, as demand for more ... is the world,s largest market for thermometers, ... advanced thermometers is Sanomedics International Holdings, Inc. ...
(Date:10/22/2014)... CHARLOTTESVILLE, Va. and AUSTIN, ... PhosImmune Inc. and PureMHC LLC today announced they ... to develop novel antibody-based immunotherapies designed to target ... identification of phosphorylated peptides displayed on the surfaces ... These phosphopeptide tumor targets (PTTs), derived from proteins ...
Breaking Medicine Technology:Surefire Medical's Scientific Advisory Board Expands, Broadens Clinical Trial Expertise 2Sanomedics International Holdings Analyst Report: Taking Some Heat by BrokerBank Securities, Inc. 2Biotech Companies To Co-Discover And Co-Develop Antibodies Targeting Novel Phosphopeptide Tumor Targets 2
(Date:10/22/2014)... HealthDay Reporter , TUESDAY, Oct. 21, ... Ebola cases in Dallas. But, mental health specialists say overblown ... President Barack Obama on Friday appointed an Ebola "czar" to ... two Dallas nurses who cared for a Liberian man who ... But the U.S. cases are miniscule in the context ...
(Date:10/22/2014)... With the Affordable Care Act (ACA) open enrollment ... Institutes for Research (AIR) finds that three out of four ... but 42 percent say they are not likely or only ... for coverage. , The AIR survey found wide gaps in ... calculate correctly how much they owe for a routine doctor’s ...
(Date:10/22/2014)... 22, 2014 Although there are only 24 hours ... many people who have trouble finding time within their busy schedules ... for long periods of time to get in shape. Here are ... on the go. , Change Up Your Commute , Consider ... to add some exercise into your daily routine. If you must ...
(Date:10/22/2014)... HealthDay Reporter , TUESDAY, Oct. 21, 2014 ... are only about half as likely as white women to ... indicates, and the racial disparity persists even when donor eggs ... white patients became pregnant after IVF, compared to about 17 ... cycles over two years to tease out the impact of ...
(Date:10/22/2014)... HealthDay Reporter , MONDAY, Oct. 20, 2014 ... guidelines for health workers treating Ebola patients, now requiring full ... respirator at all times. The U.S. Centers for Disease ... two Dallas nurses contracted Ebola while caring for the first ... Eric Duncan. Nina Pham is currently being treated for her ...
Breaking Medicine News(10 mins):Health News:Ebola Anxiety: A Bigger Threat Now Than the Virus Itself 2Health News:Ebola Anxiety: A Bigger Threat Now Than the Virus Itself 3Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 2Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 3Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 4Health News:HealthGuideMD Presents Ways to Improve Your Exercise and Fitness 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 3Health News:CDC Tightens Rules on Caring for Ebola Patients 2Health News:CDC Tightens Rules on Caring for Ebola Patients 3
... 2011 UT Southwestern Medical Center scientists are shedding ... a fast-acting antidepressant response in patients with treatment-resistant depression. ... doses as a fast-acting antidepressant potentially has use in ... a very sharp increase that immediately relieves depression," said ...
... , THURSDAY, June 16 (HealthDay News) -- The ... Barrett,s esophagus may be lower than previously thought, according ... with the premalignant condition are advised to undergo routine ... of esophageal cancer. Endoscopy involves insertion of a long, ...
... , THURSDAY, June 16 (HealthDay News) -- No ... percent of the officers from the New York Police Department,s ... on the World Trade Center, according to a new study. ... from 206 officers who responded to the attack and found ...
... Innovative adult stem cell research by scientists at The University ... efforts to apply the brakes to stem cells that produce ... appeared today online ahead of the print issue of ... bold approach for targeting fat-generating stem cells that one day ...
... , THURSDAY, June 16 (HealthDay News) -- Students who are ... beginning years of college, research has shown. However, a ... schedules, a change occurs. "Their grades actually evened out," ... at Hendrix College in Conway, Ark. By the end of ...
... FAIRFAX, Va.Evaluating patients with multiple sclerosis who have ... widening those veins with angioplastywarrants careful, well-designed research, ... Foundation,s Research Consensus Panel. And, the multidisciplinary panel ... pivotal multicenter trial are not now available, that ...
Cached Medicine News:Health News:Cancer Risk With Barrett's Esophagus May Be Lower Than Thought 2Health News:Lung Health of Police Responders From 9/11 Called 'Encouraging' 2Health News:New stem cell research could aid in battle against bulging waistlines 2Health News:Night Owls' Poor Sleep Habits Can Hurt Grades 2Health News:Night Owls' Poor Sleep Habits Can Hurt Grades 3Health News:SIR Foundation sets research priorities for minimally invasive treatments for MS patients 2Health News:SIR Foundation sets research priorities for minimally invasive treatments for MS patients 3
... Utilized for capsulotomies, nucleus dislocating, ... (bent) cystitomes are angled to ... the lens, providing easier access ... reducing the potential for corneal ...
... Left. 23 gauge thin wall ... Angled 20 degree shaft 10 mm ... set 0.5 mm behind aspiration tip. ... 46 cm (18.1 inches) of silicone ...
This specially designed 23 gauge spoon-shaped cannula is connected to a balanced salt solution bottle and with a low-flow of fluid, is designed to allow a controlled cleaning of the stromal interface...
... with five legs for extra stability. ... 25" (total vertical travel 6"). 2" ... Comfortable, durable and fire retardant upholstery, ... other colors available by special order. ...
Medicine Products: